codrituzumab

05/01/2009 - "Previously, we demonstrated the antitumor efficacy of the anti-glypican-3 (GPC3) antibody GC33 in several human liver cancer xenograft models and the important role of antibody-dependent cellular cytotoxicity (ADCC) in the antitumor mechanism of GC33. "
01/01/2016 - "In this clinical trial, codrituzumab was not found be effective against liver cancer. "
12/22/2020 - "Here, we synthesized and evaluated the efficacy of [225Ac]Ac-Macropa-GC33 in mice engrafted with the GPC3-expressing human liver cancer cell line HepG2. "
05/01/2009 - "Histopathological analyses of the antitumor activity of anti-glypican-3 antibody (GC33) in human liver cancer xenograft models: The contribution of macrophages."
01/01/2016 - "Codrituzumab is a manufactured antibody against a liver cancer protein called glypican-3. "

01/01/2016 - "Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma."
04/01/2014 - "This study aimed to assess the safety, tolerability, and pharmacokinetic characteristics of GC33 in Japanese patients with advanced hepatocellular carcinoma. "
04/01/2014 - "In the first-in-human study carried out in the USA, GC33 was well tolerated and showed preliminary antitumor activity in patients with advanced hepatocellular carcinoma. "
03/05/2018 - "I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma."
01/01/2018 - "Time-to-event modelling of effect of codrituzumab on overall survival in patients with hepatocellular carcinoma."

10/01/2023 - "Chugai Pharmaceutical has restarted its Phase I trial of GC33, continuing to explore its clinical value targeting GPC3 in solid tumors. "
05/01/2009 - "In this study, we investigated histopathologically time-course changes in xenografts in mice following a single administration of GC33 to clarify the morphological changes contributing to the tumor growth inhibition of GC33, including the changes in GPC3-related factors/components [proliferation, extracellular matrices (ECMs) and macrophage]. "
10/01/2023 - "In vitro cytotoxicity assays and in vivo experiments demonstrated that QDEB could enhance anti-tumor efficacy compared with GC33. "
01/01/2022 - "Remarkably, the tumor-infiltrating 8F8 CARTs were less exhausted and apoptotic, and more functional than GC33 CARTs. "
01/01/2022 - "Importantly, compared with GC33 CARTs, there were 5-fold more of 8F8-BBz CARTs in the tumor mass for a longer period of time. "

01/01/2016 - "185 patients were enrolled: 125 received codrituzumab and 60 placebo: Median age 64/63, 85/75% male, 46/42% Asian, ECOG 0 65/63%, 74/77% having vascular invasion and/or extra-hepatic metastasis. "